The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
|
|
- Barnaby Lloyd
- 5 years ago
- Views:
Transcription
1 The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall potential risks or benefits of a product which are based on an evaluation of an entire research program. Before prescribing any Takeda products, healthcare professionals should consult prescribing information for the product approved in their country.
2 AF37702 Page 1 of 11 1 SYNOPSIS Title of Study: A Study of AF37702 in Chronic Renal Failure Patients on Peritoneal Dialysis Name of Sponsor: Takeda Pharmaceutical Co., Ltd. Study Drug: AF37702 Trade Name: Not yet determined Investigator(s) and Study Site(s): A total of 30 study sites including Meiyokai Medical Corporation Narita Memorial Hospital (Takaaki Obayashi, Director, Department of Nephrology) (See Appendix ) Publication: None Study Period: Development Phase: Date first subject signed consent: May 24, 2010 Phase 3 Date last subject had last visit: May 7, 2011 Objectives: To evaluate efficacy, safety, and pharmacokinetics of AF37702 following subcutaneous or intravenous multiple administration, once every 4 weeks in chronic renal failure patients on peritoneal dialysis in an open-label manner. Study Design: This study was a multicenter, open-label study for evaluation of efficacy, safety, and pharmacokinetics of AF37702 following multiple administration in chronic renal failure patients on peritoneal dialysis. (1) Study population and its design This study consisted of 4 treatment groups comprising different subjects and dosing regimens. In the mg/kg SC group, study drug was administered subcutaneously to subjects who had not been on treatment with an erythropoiesis stimulating agent (ESA). In the CF0.066 SC/SC group, study drug was administered subcutaneously to subjects who were on subcutanous ESA treatment. In the CF0.066 IV/SC group, study drug was administered subcutaneously to subjects who were on intravenous ESA treatment. In the CF0.066 IV/IV group, study drug was administered intravenously to subjects who were on intravenous ESA treatment. In the mg/kg SC group, subjects who met the following criteria were included in the study: continuous peritoneal dialysis since before the start of the Screening Phase with no history of ESA treatment after the initiation of peritoneal dialysis or with no history of ESA treatment within 12 weeks (84 days) before start of the study drug administration, and hemoglobin (Hgb) values of less than 10.0 g/dl at 2 measurement time points within 8 weeks (56 days) from the day
3 AF37702 Page 2 of 11 before the initiation of study treatment. In the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups, subjects who met the following criteria were included in the study: continuous peritoneal dialysis for at least 3 months (90 days) before the start of the Screening Phase and on ESA treatment (epoetin beta, epoetin alfa, or darbepoetin alfa) for at least 8 weeks (56 days) before start of the study drug administration, and Hgb values of 10.0 to 12.0 g/dl at 2 measumement time points within 8 weeks (56 days) from the day before the initiation of study treatment. The planned number of subjects in the study was approximately 80 subjects treated with study drug (0.025 mg/kg SC group, 5 subjects; CF0.066 SC/SC group, 25 subjects; CF0.066 IV/SC group, 25 subjects; CF0.066 IV/IV group, 25 subjects). The total study duration was 26 to 28 weeks (up to 6 doses of the study drug) consisting of the Screening Phase (2 to 4 weeks) and Treatment Phase (24 weeks). The tests/examinations and observations specified in the protocol were performed during the study period. (2) Dosage and mode of administration The initial dose in the mg/kg SC group was the predetermined doses (1.0, 1.25, 1.5, 2.0, and 2.5 mg/4 weeks) based on the subjects body weight at Week 0. Subsequent doses were adjusted (unchanged, 1-step decrease, 1-step increase, or delayed) within the range of 0.5 to 6.0 mg every 4 weeks based on Hgb values of individual subjects. The second administration was delayed if the Hgb value exceeded 13.0 g/dl in any of the specified time points following initial treatment (except for the day of initial treatment), while the subsequent administration was delayed when the Hgb value exceeded 12.5 g/dl in any of the specified time points following the preceding treatment (except for the day of the preceding treatment). Administration of the study drug was resumed at 1-step decreased dose and continued every 4 weeeks, from the first even-numbered week after the Hgb value firstly decreased to 12.5 g/dl or less for the delay of 2nd adminitsration and from the first even-numbered week after the value firstly decreases to 12.0 g/dl or less for the dalay of subsequent administration. The initial dose in the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups was the predetermined doses (0.75, 1.0, 1.25, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 mg/4 weeks) specified according to prescribed ESA doses within the 2 weeks before start of the study drug administration. The subsequent doses were adjusted (unchanged, 1-step decreased, 1-step increased, 2-step increased, or delayed) at a range of 0.5 to 20.0 mg every 4 weeks based on individual Hgb value. Administration was delayed when the Hgb value exceeded 12.5 g/dl in any of the specified time points following the preceding treatment (except for the day of the preceding treatment), and administration of AF37702 was resumed at a 1-step decreased dose and continued every 4 weeks from the first even-numbered week after the Hgb value first decreased to 12.0 g/dl or less. When switching from ESA preparation to study drug, the dosing interval was to be determined according to the dose frequency of ESA preparation before the switching; at least 2 days (twice or thrice per week administration), at least 7 days (once per week administration), at least 14 days (once per 2-week administration), or at least 28 days (every 4 weeks) since the day of final
4 AF37702 Page 3 of 11 administration of ESA. (3) Study schedule Subjects visited study sites every week until Week 4, and thereafter every other week during the period to Week 24. Laboratory tests, electrocardiogram (ECG) tests, observation of subjective symptoms/objective findings, and others were performed on the day of the test/examination specified in the protocol. Blood sampling for analysis of plasma drug concentration was also performed in subjects given the study drug intravenously. A schematic of the study design is shown below. Informed consent (prior to the Screening Phase) Start of Screening Phase Enrollment Final examination Screening Treatment (without dose delay) Weeks -4 to -2 Week 0 Note2) Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Note 1) Not on ESA treatment mg/kg SC group: 5 subjects AF37702 subcutaneous administration On ESA treatment (subcutaneous administration) On ESA treatment (intravenous administration) Note 1), Note 2) CF0.066 SC/SC group: 25 subjects AF37702 subcutaneous administration Note 1), Note 2) CF0.066 IV/SC group: 25 subjects AF37702 subcutaneous administration Note 1), Note 2) CF0.066 IV/IV group: 25 subjects AF37702 intravenous administration 1st administration 2nd 3rd 4th 5th 6th Number of Subjects: Planned: Note 1): Doses were adjusted according to individual Hgb value. Note 2): When switching from ESA preparation to study drug, the dosing interval was at least 2 days (twice or thrice per week administration), at least 7 days (once per week administration), at least 14 days (once per 2-week administration), or at least 28 days (every 4 weeks) since the day of final administration of ESA. A schematic of the study design Number of subjects who were to receive the study drug administration: Approximately 80 subjects Analyzed: mg/kg SC group: 5 subjects CF0.066 SC/SC group: 25 subjects CF0.066 IV/SC group: 25 subjects CF0.066 IV/IV group: 25 subjects Full Analysis Set (FAS): 101 subjects (10 in the mg/kg SC group, 28 in the CF0.066 SC/SC group, 29 in the CF0.066 IV/SC group, and 34 in the CF0.066 IV/IV group) Per Protocol Set (PPS): 93 subjects (9 in the mg/kg SC group, 27 in the CF0.066 SC/SC group, 26 in the CF0.066 IV/SC group, and 31 in the CF0.066 IV/IV group)
5 AF37702 Page 4 of 11 Inclusion Criteria: (1) All treatment groups 1) Those aged 20 or more at the time of obtaining the informed consent 2) Male or females 3) Those who had serum ferritin level of 100 ng/ml or more, or had transferrin saturation of 20% or more at the Screening Phase 4) Among those who were capable of giving consent to participate in the study, and understanding the informed consent form and other explanatory documents, those who had given written consent (2) Subjects not on ESA treatment (0.025 mg/kg SC group) 5) Those who had received peritoneal dialysis continuously since before the Screening Phase 6) Those who had not received ESA treatment after the start of peritoneal dialysis or within 12 weeks (84 days) before start of the study drug administration 7) Those who had the 2 most recent Hgb values (with an interval of not less than 5 days between 2 measurements, and one of the measurements performed within 14 days before start of the study drug administration) of less than 10.0 g/dl within 8 weeks (56 days) before start of the study drug administration (3) Subjects on ESA treatment (CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups) 8) Those who had received peritoneal dialysis continuously for 3 months (90 days) or more prior to the Screening Phase 9) Those who had received ESA treatment (epoetin beta, epoetin alfa, or darbepoetin alfa) continuously for 8 weeks (56 days) or more before start of the study drug administration; however, the change in regimen is not allowed within 2 weeks (14 days) before start of the study drug administration 10) Those who had the 2 most recent Hgb values (with an interval of not less than 5 days between 2 measurements, and one of the measurements performed within 14 days before start of the study drug administration) of 10.0 to 12.0 g/dl within 8 weeks (56 days) before start of the study drug administration. Exclusion Criteria: 1) Those who were known to be intolerant to any ESA 2) Those who were known to be intolerant to iron preparations 3) Those who received red blood cell or whole blood transfusion within 12 weeks (84 days) before start of the study drug administration 4) Those having hemoglobinopathy (sickle cell disease, thalassemia, etc.) 5) Those who had present or past history of any hemolytic disease 6) Those having poorly controlled inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, etc.) 7) Those who had suffered from moderate to severe infection within 2 weeks (14 days) before start of the study drug administration 8) Those having poorly controlled secondary hyperparathyroidism 9) Those having poorly controlled hypertension 10) Those with a history of epileptic seizure within 6 months (180 days) before start of the
6 AF37702 Page 5 of 11 study drug administration 11) Those who had a present or past history of chronic heart failure (class III or IV according to NYHA classification) 12) Those who had present or past history of malignant tumor within past 5 years before start of the study drug administration 13) Those who had a plan to undergo a surgery with a massive hemorrhage during the study period 14) Those who were pregnant, lactating, or potentially pregnant, and those of child-bearing potential and using no contraceptive measure 15) Those who had a present or past history of drug or alcohol abuse 16) Those who had a present or past history of hypersensitivity or allergy to peptide preparations, PEG, or protein preparations 17) Those who had suffered peritonitis or catheter infection that would interfere with continuous peritoneal dialysis within 8 weeks (56 days) prior to the study treatment 18) Those who had received hemodialysis concurrently (except for emergency management) 19) Those who were expected to receive maintenance hemodialysis during the study period (including combination therapy with peritoneal dialysis) 20) Those who had previous exposure to any study drug (including that used in post-marketing clinical studies) within 12 weeks (84 days) before start of the study drug administration 21) Those who had previous exposure to AF ) Those who were likely to drop out early from the study or discontinue the study (for example, subjects who showed the following diseases or conditions within 1 year prior to the study drug administration; myocardial infarction, severe or unstable coronary disease, cerebral stroke, severe or unstable respiratory diseases including reactive airways disease, autoimmune disorder, neuropsychiatric disorder, neurological disorder, viral liver disease such as active hepatitis B or C, active HIV disease, a past history of serious allergy to multiple drugs, or other clinically serious diseases or conditions that were judged by the investigator or subinvestigator to be difficult for safety, evaluation, or follow-up of the subject) 23) Those who were considered ineligible to participate in this study by the investigator or subinvestigator Test Product, Dose, Mode of Administration, and Lot Number: Dosage form and content: AF37702 injection (10 mg/1 ml): An injectable solution containing 10 mg of AF37702 per vial (1 ml). The additives include sorbitol (47 mg), sodium dihydrogenphosphate (2.99 mg), anhydrous disodium phosphate (0.117 mg), sodium hydroxide (appropriate amount), polysorbate 20 (0.03 L), and water for injection (1 ml in total). AF37702 diluent (1 ml): An injectable solution containing the following ingredients per vial (1 ml): Sorbitol (47 mg), sodium dihydrogenphosphate (2.99 mg), anhydrous disodium phosphate (0.117 mg), sodium hydroxide (appropriate amount), polysorbate 20 (0.03 L), and water for injection (1 ml in total) Dosage and regimen: (1) mg/kg SC group
7 AF37702 Page 6 of 11 Every 4 weeks, subcutaneous administration Initial dose: 1.0 to 2.5 mg (determined based on the subject s body weight at Week 0) Subsequent doses (after Week 4): Doses were adjusted within the range of 0.5 to 6.0 mg based on the Hgb value of individual subjects. (2) CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups CF0.066 SC/SC and CF0.066 IV/SC groups: Every 4 weeks, subcutaneous administration CF0.066 IV/IV group: Every 4 weeks, intravenous administration Initial dose: 0.75 to 8.0 mg (determined according to the prescribed ESA dose within 2 weeks before study treatment initiation) Subsequent doses (after Week 4): Doses were adjusted within the range of 0.5 to 20.0 mg based on the Hgb value of individual subjects. * Up to 6 doses of the study drug were to be given. Batch/Lot No. Study Drug Batch/Lot Number Expiration Date AF37702 injection (AF37702 diluent) AF37702 injection (AF37702 diluent) (for additional delivery) Z (Z377Q01) September 2011 Z (Z377Q03) January 2012 Z (Z377Q01) September 2011 Z (Z377Q03) January 2012 Period of Evaluation: Screening Phase (2 to 4 wks) + Treatment Phase (24 wks)(if there is no dose delay)
8 AF37702 Page 7 of 11 Main Endpoints: (1) Efficacy Primary endpoint; Proportion of subjects (%) whose mean Hgb values from Week 16 to Week 24 were within a range of 10.0 to 12.0 g/dl Secondary endpoint; Changes from baseline of mean Hgb values from Week 16 to Week 24 Other endpoints; Proportion of subjects (%) whose mean Hgb values from Week 16 to Week 24 were within a range of 11.0 to 12.0 g/dl Time profiles of Hgb value Time profiles of the Hgb changes from baseline Proportion of subjects (%) with no dose adjustment Pharmacodynamic parameters (reticulocyte count [absolute], RBC count, hematocrit, serum ferritin concentration, transferrin saturation, transferrin receptor protein) (2) Safety Adverse events (AEs) Laboratory test results ECG Vital signs (3) Pharmacokinetics Plasma concentrations of unchanged AF37702
9 AF37702 Page 8 of 11 Statistical Methods: Frequency distribution was presented per treatment group using the FAS for the proportion of subjects whose mean Hgb values from Week 16 to Week 24 were within a range of 10.0 to 12.0 g/dl. SUMMARY OF RESULTS Subject Disposition: A total of 135 subjects provided informed consent for this study. Of these, 101 subjects received study drug. Of the subjects who received the study drug, 89 subjects completed the study, consisting of 8 subjects in the mg/kg SC group, 26 subjects in the CF0.066 SC/SC group, 26 subjects in the CF0.066 IV/SC group, and 29 subjects in the CF0.066 IV/IV group. Efficacy Conclusions: In the mg/kg SC group, including the subjects not on ESA treatment, the proportion of subjects (%) whose mean Hgb values from Week 16 to Week 24 were within a range of 10.0 to 12.0 g/dl (2-sided 95% confidence interval [CI]), defined as the primary endpoint, was 88.9% (8/9) (51.750, ). The mean Hgb change from baseline during the period from Week 16 through Week 24 (mean standard deviation [SD]), defined as the secondary endpoint, was g/dl. The results of the other endpoints were as follows: the proportion of subjects (%) whose mean Hgb values from Week 16 to Week 24 were within a range of 11.0 to 12.0 g/dl was 55.6% (5/9), and the Hgb changes from baseline at Week 4 were 2.0 g/dl (0.5 g/dl/week) or less in all subjects. For the time profiles of Hgb values, the time point when the mean Hgb value first exceeded 10.0 g/dl was Week 6. Thereafter, the mean Hgb value was maintained within the range of 10.0 to 12.0 g/dl at all dosing points. For the time profiles of Hgb changes from baseline, the time points when the mean Hgb changes from baseline first exceeded 1.0 g/dl and 2.0 g/dl were Weeks 6 and 14, respectively. The AF37702 doses (mean SD) were mg for the first administration and mg for the sixth administration. The AF37702 dose (mean SD) administered during the period from Week 16 through Week 24 was mg. Based on the above results, it was indicated that, in chronic renal failure patients who were on peritoneal dialysis and not on ESA treatment, AF37702 started at the initial dose determined based on the mg/kg dose and adjusted appropriately at subsequent doses was able to achieve and maintain Hgb values within the target range (10.0 to 12.0 g/dl), without a rapid Hgb increase. In the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups, including subjects on ESA treatment, the proportion of subjects (%) whose mean Hgb values from Week 16 to Week 24 were within a range of 10.0 to 12.0 g/dl (2-sided 95% CI), defined as the primary endpoint, was 77.8% (21/27) (57.742, ), 85.2% (23/27) (66.269, ), and 87.1% (27/31) (70.166, ), respectively. Mean Hgb changes from baseline during the period from Week 16 through Week 24 (mean SD), defined as the secondary endpoint, were g/dl, g/dl, and g/dl in the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups, respectively.
10 AF37702 Page 9 of 11 The results of the other endpoints were as follows: the proportion of subjects (%) whose mean Hgb values from Week 16 to Week 24 were within a range of 11.0 to 12.0 g/dl was 59.3% (16/27), 59.3% (16/27), and 64.5% (20/31) in the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups, respectively. The proportion of subjects (%) whose Hgb changes from baseline were within 1.0 g/dl from Week 16 through Week 24 was 77.8% (21/27), 74.1% (20/27), and 90.3% (28/31) in the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups, respectively. For the time profiles of the Hgb values, mean Hgb values were maintained within the range of 10.0 to 12.0 g/dl throughout the study period in all groups. For the time profiles of Hgb changes from baseline, mean Hgb changes from baseline were maintained at 1.0 g/dl or less throughout the study period in all groups except for Week 10 in the CF0.066 SC/SC group. The AF37702 doses (mean SD) in the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups were mg, mg, and mg, respectively, for the first administration, and mg, mg, and mg, respectively, for the sixth administration. The AF37702 doses (mean SD) administered during the period from Week 16 through Week 24 were mg, mg, and mg in the CF0.066 SC/SC, CF0.066 IV/SC, and CF0.066 IV/IV groups, respectively. Based on the above results, it was indicated that, in patients with chronic renal failure who were on peritoneal dialysis and on ESA treatment, when switching from subcutaneous or intravenous ESA treatment to subcutaneous or intravenous AF37702 administration, AF37702 started at the initial switching dose determined based on the conversion factor of and adjusted appropriately at subsequent doses was able to maintain Hgb values within the target range (10.0 to 12.0 g/dl) stably. Safety Conclusions: The incidence of adverse events (AEs) was 80.0% (8/10, 45 events) in the mg/kg SC group, 89.3% (25/28, 103 events) in the CF0.066 SC/SC group, 89.7% (26/29, 90 events) in the CF0.066 IV/SC group, and 85.3% (29/34, 128 events) in the CF0.066 IV/IV group. Of all the AEs, those occurring in 2 or more subjects in all treatment groups were nasopharyngitis and hypertension. Of these, hypertension in 13 subjects (0.025 mg/kg SC group, 1 subject; CF0.066 SC/SC group, 2 subjects; CF0.066 IV/SC group, 5 subjects; and CF0.066 IV/IV group, 5 subjects) were considered to be related to study drug. However, since all events were mild in severity, study treatment was continued. There was no clear trend noted in the incidence of AEs by period in any of the groups or in the incidence of individual AEs by period. The incidence of AEs considered to be related to study drug was 30.0% (3/10, 5 events) in the mg/kg SC group, 32.1% (9/28, 13 events) in the CF0.066 SC/SC group, 27.6% (8/29, 11 events) in the CF0.066 IV/SC group, and 29.4% (10/34, 16 events) in the CF0.066 IV/IV group. Of these, AEs considered to be related to study drug occurring in 2 subjects or more in any of the treatment groups were hypertension, blood pressure increased, and blood alkaline phosphatase
11 AF37702 Page 10 of 11 increased. The incidence of these AEs was as follows: hypertension: 10.0% (1/10) in the mg/kg SC group, 7.1% (2/28) in the CF0.066 SC/SC group, 17.2% (5/29) in the CF0.066 IV/SC group, and 14.7% (5/34) in the CF0.066 IV/IV group; blood pressure increased: 7.1% (2/28) in the CF0.066 SC/SC group only; and blood alkaline phosphatase increased: 5.9% (2/34) in the CF0.066 IV/IV group only. All of these events were mild in severity and study treatment was continued. The majority of AEs were mild or moderate in severity, and severe AEs were observed only in the CF0.066 IV/IV group (8.8% (3/34, 4 events)). Details of severe AEs were 1 event each of dehydration, peritonitis, sepsis, and rectal ulcer haemorrhage (sepsis and rectal ulcer haemorrhage occurred in the same subject). All of these were assessed as not related to study drug. There was no AE leading to death during the study period. Serious adverse events (SAEs) occurred in 4 subjects (5 events) in the mg/kg SC group, 3 subjects (5 events) in the CF0.066 SC/SC group, 4 subjects (9 events) in the CF0.066 IV/SC group, and 7 subjects (11 events) in the CF0.066 IV/IV group. Of these, SAEs considered to be related to study drug were acute myocardial infarction (1 subject) in the CF0.066 SC/SC group, thrombotic cerebral infarction and cardiac failure (occurred in the same subject) in the CF0.066 IV/SC group, and somnolence (1 subject) in the CF0.066 IV/IV group. Each of these events was also considered to be related to subject background characteristics or concomitant medications. The incidence of AEs leading to discontinuation of study treatment was 30.0% (3/10, 3 events) in the mg/kg SC group, 3.6% (1/28, 1 event) in the CF0.066 SC/SC group, 13.8% (4/29, 5 events) in the CF0.066 IV/SC group, and 11.8% (4/34, 7 events) in the CF0.066 IV/IV group. There was no AE leading to discontinuation of study treatment that occurred in 2 subjects or more in any of the treatment groups. AEs leading to discontinuation of study treatment that were considered to be related to the study drug were hepatic function abnormal in the mg/kg SC group, acute myocardial infarction in the CF0.066 SC/SC group, lymphadenopathy, thrombotic cerebral infarction, cardiac failure, and hypertension in the CF0.066 IV/SC group, and somnolence and macular oedema in the CF0.066 IV/IV group. All of these occurred in 1 subject each (of these, thrombotic cerebral infarction and cardiac failure in the CF0.066 IV/SC group occurred in the same subject). For laboratory tests, vital signs, and ECG, several time points were assessed as abnormal and clinically significant for 12-lead ECG findings in only 1 subject in the CF0.066 SC/SC group (subject number: ). These findings were diagnosed as acute myocardial infarction and were reported as an SAE related to the study drug. Except these, there were no clinically significant changes, and no clinically significant AEs associated with these were reported. None of the subjects received red blood cell transfusion during the period from study treatment initiation to study completion or discontinuation. Anti-AF37702 antibody was detected in 2 subjects (CF0.066 SC/SC group, 1 subject; CF0.066 IV/SC group, 1 subject). There was no decrease in Hgb values or occurrence of relevant AEs in either of these subjects after antibody detection. In addition, the antibodies detected in these 2 subjects showed no neutralization activity or cross-reaction with erythropoietin (EPO). The
12 AF37702 Page 11 of 11 anti-af37702 antibody testing was confirmed to have reverted to negative during the study period in 1 subject and during the follow-up period in the other subject. Based on the above results, it was considered that there was no significant safety concern with subcutaneous or intravenous multiple administrations of AF37702 in chronic renal failure patients on peritoneal dialysis. OVERALL CONCLUSIONS The efficacy, safety, and pharmacokinetics following subcutaneous or intravenous multiple administration of AF37702 every 4 weeks were evaluated in chronic renal failure patients on peritoneal dialysis in an open-label manner. With regard to efficacy, it was considered that, in patients with chronic renal failure who were on peritoneal dialysis and not on ESA treatment, AF37702 started at the initial dose determined based on the mg/kg dose and adjusted appropriately at subsequent doses was able to achieve and maintain Hgb values within the target range (10.0 to 12.0 g/dl), without a rapid Hgb increase. It was also considered that, in patients with chronic renal failure who were on peritoneal dialysis and on ESA treatment, when switching from subcutaneous or intravenous ESA treatment to subcutaneous or intravenous AF37702 administration, AF37702 started at the initial switching dose determined based on the conversion factor of and adjusted appropriately at subsequent doses was able to maintain Hgb values within the target range (10.0 to 12.0 g/dl) stably. With regard to safety, it was considered that there was no significant safety concern with subcutaneous or intravenous multiple administrations of AF37702 in chronic renal failure patients on peritoneal dialysis. Based on the above results, it was considered that, in chronic renal failure patients on peritoneal dialysis, every 4 weeks subcutaneous or intravenous multiple administration of AF37702 could gradually increase Hgb values to achieve and stably maintain within target Hgb values for patients not on ESA treatment, and also could be switched from other ESA treatment without large fluctuation of Hgb values and maintain Hgb values stably for patients on ESA treatment. Date of Report: January 30, 2012
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information2.0 Synopsis. ABT-358/Paricalcitol M Clinical Study Report R&D/09/1255. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Title of Study: Late Phase II Study of Paricalcitol Injection Dose-response study of paricalcitol injection in chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationARANESP (darbepoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2001
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP (darbepoetin
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationYoung Ki Lee, Sung Gyun Kim, Jang Won Seo, Ji Eun Oh, Jong-Woo Yoon, Ja-Ryong Koo, Hyung Jik Kim and Jung Woo Noh
Nephrol Dial Transplant (2008) 23: 3240 3246 doi: 10.1093/ndt/gfn255 Advance Access publication 9 May 2008 Original Article A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc., a Pfizer company, at , or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT (epoetin
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationPage: 17 December 2012 (Study M13-692) 22 October 2013 (Study M13-692)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: D2E7 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Studies:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL EDUCATIONAL PACKAGE TABLE OF CONTENTS:
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT TABLE OF CONTENTS: PROTOCOL EDUCATIONAL PACKAGE Page 2: CANN-NET Anemia Management Protocol: Educational Document
More informationMIRCERA. INN: Methoxy polyethylene glycol-epoetin beta. Pre-filled syringe. Composition
MIRCERA INN: Methoxy polyethylene glycol-epoetin beta Pre-filled syringe Composition Single dose pre-filled syringes: containing 50µg, 75µg, 100µg, 150µg, 200µg, or 250µg methoxy polyethylene glycol-epoetin
More informationPROCRIT (epoetin alfa) for Injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. PROCRIT (epoetin alfa)
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFor National Authority Use Only. Affymax, Incorporated. AF37702 Injection AF37702
Dr. Peter Harper, Guys and St. Thomas Hospital, London, UK; Dr. Karel Cwiertka, Facultni Nemocnice Olomouc, Olomouc, Czech Republic; Dr. Jiri Petera, University Hospital, Hradec Karlova, Czech Republic;
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin zeta, 1000 IU/0.3ml, 2000 IU/0.6ml, 3000 IU/0.9ml, 4000 IU/0.4ml, 5000 IU/0.5ml, 6000 IU/0.6ml, 8000 IU/0.8ml, 10,000 IU/1.0ml, 20,000 IU/0.5ml, 30,000 IU/0.75ml and
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550
More informationChapter 3: Use of ESAs and other agents* to treat anemia in CKD Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 3 & 2012 DIGO Chapter 3: Use of ESAs and other agents* to treat anemia in CD idney International Supplements (2012) 2, 299 310; doi:10.1038/kisup.2012.35 ESA
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationPeer Review Report. [erythropoietin-stimulating agents]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [erythropoietin-stimulating agents] (1) Does the application adequately address the issue of the public health need
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationPFIZER INC. Study Center(s): A total of 6 centers took part in the study, including 2 in France and 4 in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSynopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationPFIZER INC. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx / Fosphenytoin Sodium
PFIZER INC These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Policy Title: Erythropoietin for end-stage renal disease
Clinical Policy Title: Erythropoietin for end-stage renal disease Clinical Policy Number: 00.02.07 Effective Date: June 1, 2015 Initial Review Date: February 19, 2014 Most Recent Review Date: January 11,
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationPROCRIT DOSAGE AND ADMINISTRATION PROCRIT
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. injection, for intravenous
More informationProduct name: Nespo EMEA/H/C/000333/II/0036 SCIENTIFIC DISCUSSION. Medicinal product no longer authorised
Product name: Nespo EMEA/H/C/000333/II/0036 SCIENTIFIC DISCUSSION 1 1. Introduction Darbepoetin alfa (Aranesp /Nespo ) was approved in the European Union in June 2001 via a centralised procedure. Its active
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Epoetin alfa HEXAL 1,000 IU/0.5 ml solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2,000 IU/1 ml solution
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNESP Injection 5µg Plastic Syringe NESP Injection 180 µg Plastic Syringe
Kyowa Hakko Kirin Co., Ltd. 1 Revised :February 2018 (6th version, the result of reexamination, and the others) Standard Commodity Classification No. of Japan 873999 - Long-Acting Erythropoiesis Stimulating
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationClinical Policy Title: Erythropoietin for end-stage renal disease
Clinical Policy Title: Erythropoietin for end-stage renal disease Clinical Policy Number: 00.02.07 Effective Date: June 1, 2015 Initial Review Date: February 19, 2014 Most Recent Review Date: January 18,
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationAdalimumab M Clinical Study Report Final R&D/17/0360
Methodology (Continued): Beginning at Week 8, subjects who developed a flare while receiving ew therapy or had a PCDAI 15 points higher than Baseline at any time during this study may have been discontinued
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Dynepo 1,000 IU/0.5 ml solution for injection in a pre-filled syringe. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pre-filled
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1054. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationSYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.
Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and
More informationJanssen Pharma. For excipients, see List of Excipients.
EPREX Janssen Pharma PRODUCT NAME EPREX (Epoetinum alfa) Pre-filled Syringes with needle guard (PROTECS ) DOSAGE FORMS AND STRENGTHS Epoetinum alfa, a glycoprotein produced by recombinant DNA technology,
More informationClinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia
Clinical and Cost Effectiveness of Darbepoetin alfa in Cancer Treatment-induced Anaemia 8 th November 2004 A report for the National Institute for Clinical Excellence prepared by Amgen Ltd. EXECUTIVE SUMMARY
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More information12.1 Mechanism of Action OMONTYS in patients with CKD on dialysis Carcinogenesis, Mutagenesis, Impairment of Fertility 4 CONTRAINDICATIONS
HIGHLIGHTS F PRESCRIBING INFRMATIN These highlights do not include all the information needed to use MNTYS safely and effectively. See full prescribing information for MNTYS. MNTYS (peginesatide) Injection,
More information